Study highlights tragedy of avoidable adverse drug reactions

Following the publication of a study into the frequency of Adverse Drug Reactions, First DataBank has spoken out at the tragedy of these avoidable and sometimes fatal errors. The study by PLos One entitled "Adverse Drug Reactions in Hospital In - Patients: A Prospective Analysis of 3695 Patient-Episodes" was covered this week by the BBC and highlighted that "one in seven hospital patients experience adverse drug reactions, half of which are completely avoidable". The study identifies electronic prescribing as one of the possible intervention strategies in the reduction of adverse drug reactions.

David Flavell, President at First DataBank International comments, "The real tragedy of this study is that injury and death caused by adverse drug reactions, doesn't have to happen. There are electronic prescribing systems (with integrated clinical decision support) available which are able to prevent medication errors. Such systems are demonstrating real benefits in the hospitals where they have already been introduced."

"These systems support clinicians in their decision making by flagging up potential adverse drug reactions. At the point that a clinician prescribes a medication to a patient, the clinical decision support checks the medication against information held in the patient's Electronic Health Record and generates an on-screen alert message if there are potential clinical problems."

Mr Flavell concludes, "Paper-based systems are no longer an acceptable means of recording and cross checking patient records against potential interactions. We strongly urge more hospitals to consider transferring from paper-based systems, which can be subject to error, to reduce the risk of adverse drug reactions and improve patient safety."

About First DataBank Europe
First DataBank Europe (FDBE) is the UK's leading provider of drug knowledge bases and active clinical decision support. With over 25 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, FDBE has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen FDBE to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

Our Multilex Drug Data File - the UK's most comprehensive and widely used drug knowledge base - is in daily use by thousands of healthcare professionals in the UK.

For further information visit www.firstdatabank.co.uk.

BBC News: Hospital drug reactions 'common'

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...